These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
683 related items for PubMed ID: 16377864
21. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. Fleck R, Dietz A, Hof H. J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369 [Abstract] [Full Text] [Related]
22. [Identification and antifungal susceptibility of Candida spp isolated from invasive mycoses. Influence of growth inhibition percentage to determine minimal inhibitory concentration]. Alvarado D, Díaz MC, Silva V. Rev Med Chil; 2002 Apr; 130(4):416-23. PubMed ID: 12090107 [Abstract] [Full Text] [Related]
27. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Swinne D, Watelle M, Van der Flaes M, Nolard N. Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180 [Abstract] [Full Text] [Related]
28. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing and the Clinical Laboratory Standards Institute BMD method for non-Candida albicans and non-C. tropicalis bloodstream isolates from eleven tertiary hospitals in São Paulo state, Brazil. Purisco SU, Martins MA, Szeszs MW, Castro e Silva DM, Pukinskas SR, Bonfietti LX, Baez AA, Melhem MS. FEMS Yeast Res; 2012 Dec; 12(8):890-6. PubMed ID: 22883021 [Abstract] [Full Text] [Related]
29. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaller MA. J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878 [Abstract] [Full Text] [Related]
30. Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data. Samonis G, Kofteridis DP, Saloustros E, Giannopoulou KP, Ntziora F, Christidou A, Maraki S, Falagas ME. Scand J Infect Dis; 2008 Feb; 40(5):414-9. PubMed ID: 18418802 [Abstract] [Full Text] [Related]
31. Molecular epidemiology of Candida species isolated from urine at an intensive care unit. Ergon MC, Gülay Z. Mycoses; 2005 Mar; 48(2):126-31. PubMed ID: 15743431 [Abstract] [Full Text] [Related]
34. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002. Yang YL, Li SY, Cheng HH, Lo HJ, TSARY Hospitals. Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603 [Abstract] [Full Text] [Related]
35. Susceptibility of candida isolates from denture-related stomatitis to antifungal agents in vitro. Dorocka-Bobkowska B, Konopka K. Int J Prosthodont; 2007 Mar; 20(5):504-6. PubMed ID: 17944341 [Abstract] [Full Text] [Related]
36. Susceptibility profile of 200 bloodstream isolates of Candida spp. collected from Brazilian tertiary care hospitals. Colombo AL, Nakagawa Z, Valdetaro F, Branchini ML, Kussano EJ, Nucci M. Med Mycol; 2003 Jun; 41(3):235-9. PubMed ID: 12964715 [Abstract] [Full Text] [Related]
37. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans. De Logu A, Saddi M, Cardia MC, Borgna R, Sanna C, Saddi B, Maccioni E. J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140 [Abstract] [Full Text] [Related]
38. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Cheng MF, Yu KW, Tang RB, Fan YH, Yang YL, Hsieh KS, Ho M, Lo HJ. Diagn Microbiol Infect Dis; 2004 Jan; 48(1):33-7. PubMed ID: 14761719 [Abstract] [Full Text] [Related]